Puma Biotechnology | PBYI - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Esperion Therapeutics USD 300.36M 451K 2026-03
Exelixis USD 370.98M 34.67M 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.49B 25.52M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
Moderna USD 2.4B 408M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Takeda JPY 2.43T 180.65B 2026-03
TG Therapeutics USD 187.11M 33.35M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03